Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An M2-V27A channel blocker demonstrates potent in vitro and in vivo antiviral activities against amantadine-sensitive and -resistant influenza A viruses.

Antiviral research - 1 Apr 2017

Hu Yanmei, Musharrafieh Rami, Ma Chunlong, Zhang Jiantao, Smee Donald F, DeGrado William F, Wang Jun

Abstract excerpt

Adamantanes such as amantadine (1) and rimantadine (2) are FDA-approved anti-influenza drugs that act by inhibiting the wild-type M2 proton channel from influenza A viruses, thereby inhibiting the uncoating of the virus. Although adamantanes have been successfully used for more than four decades, their efficacy was curtailed by emerging drug resistance. Among the limited number of M2 mutants that confer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amantadine
Share to Influenza A virus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Influenza, Human

Share to Inhibitory Concentration 50

Share to Madin Darby Canine Kidney Cells

Share to Orthomyxoviridae Infections

Share to Spiro Compounds

Share to Viral Matrix Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 28087313
DOI: 10.1016/j.antiviral.2017.01.006
PMCID: PMC5326599

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An M2-V27A channel blocker demonstrates potent in vitro and in vivo antiviral activities against amantadine-sensitive and -resistant influenza A viruses.PMID 28087313Read ↗

Slow but Steady Wins the Race: Dissimilarities among New Dual Inhibitors of the Wild-Type and the V27A Mutant M2 Channels of Influenza A Virus.Semantic proximity Read ↗

A Study of the Activity of Adamantyl Amines against Mutant Influenza A M2 Channels Identified a Polycyclic Cage Amine Triple Blocker, Explored by Molecular Dynamics Simulations and Solid-State NMR.Semantic proximity Read ↗

Discovery of novel dual inhibitors of the wild-type and the most prevalent drug-resistant mutant, S31N, of the M2 proton channel from influenza A virus.Semantic proximity Read ↗

Easily accessible polycyclic amines that inhibit the wild-type and amantadine-resistant mutants of the M2 channel of influenza A virus.Semantic proximity Read ↗

Antiviral mechanisms and preclinical evaluation of amantadine analogs that continue to inhibit influenza A viruses with M2S31N-based drug resistance.Semantic proximity Read ↗

Discovery of M2 channel blockers targeting the drug-resistant double mutants M2-S31N/L26I and M2-S31N/V27A from the influenza A viruses.Semantic proximity Read ↗

How do aminoadamantanes block the influenza M2 channel, and how does resistance develop?Semantic proximity Read ↗

Chemical Probes for Blocking of Influenza A M2 Wild-type and S31N Channels.Semantic proximity Read ↗

X-ray Crystal Structures of the Influenza M2 Proton Channel Drug-Resistant V27A Mutant Bound to a Spiro-Adamantyl Amine Inhibitor Reveal the Mechanism of Adamantane Resistance.Semantic proximity Read ↗

Structural comparison of the wild-type and drug-resistant mutants of the influenza A M2 proton channel by molecular dynamics simulations.Semantic proximity Read ↗

Recent progress in designing inhibitors that target the drug‐resistant M2 proton channels from the influenza A virusesSemantic proximity Read ↗

Flu channel drug resistance: a tale of two sites.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.